Merck & Company Inc (MRK)vsPhibro Animal Health Corporation (PAHC)
MRK
Merck & Company Inc
$130.40
-1.11%
HEALTHCARE · Cap: $307.25B
PAHC
Phibro Animal Health Corporation
$36.95
+1.59%
HEALTHCARE · Cap: $1.34B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 4284% more annual revenue ($65.77B vs $1.50B). MRK leads profitability with a 13.6% profit margin vs 6.3%. PAHC appears more attractively valued with a PEG of 1.68. PAHC earns a higher WallStSmart Score of 65/100 (C+).
MRK
Hold50
out of 100
Grade: D+
PAHC
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-62.3%
Fair Value
$81.23
Current Price
$130.40
$49.17 premium
Margin of Safety
-11.4%
Fair Value
$46.24
Current Price
$36.95
$9.29 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Every $100 of equity generates 26 in profit
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Smaller company, higher risk/reward
6.3% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : PAHC
The strongest argument for PAHC centers on Return on Equity, P/E Ratio. Revenue growth of 10.3% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : PAHC
The primary concerns for PAHC are PEG Ratio, Market Cap, Profit Margin. Debt-to-equity of 2.18 is elevated, increasing financial risk.
Key Dynamics to Monitor
PAHC carries more volatility with a beta of 0.46 — expect wider price swings.
PAHC is growing revenue faster at 10.3% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
PAHC scores higher overall (65/100 vs 50/100) and 10.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Phibro Animal Health Corporation
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Phibro Animal Health Corporation develops, manufactures and supplies a range of mineral nutrition and animal health products for livestock primarily in the United States. The company is headquartered in Teaneck, New Jersey.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?